The combination of a lung cancer vaccine plus chemotherapy has been proven to help more patients live without their cancer progressing than chemotherapy alone, a study has revealed.
The research, led by the University of Strasbourg, involved 148 patients with non-small-cell lung cancer, the most common form of the disease.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Results published in The Lancet Oncology showed that 43% of the 74 patients treated with Trasgene’s TG4010 vaccine in combination with chemotherapy survived for six months without the disease progressing, while the progression-free survival rate in the 74 patients treated with chemotherapy alone was 35%.
TG4010 is designed to trigger the immune system and target the MUC1 protein, which is overproduced by tumour cells in advanced lung cancer.
France-based gene therapy group Transgene funded the phase IIb trial.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
